Search | Clinical Trials Finder

Conditions: Disease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV Infections
Interventions: Zidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 2 Days
Enrollment: 1,735 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Long Beach, California • Gainesville, Florida • Jacksonville, Florida + 2 more

Conditions: HIV Infections
Interventions: Oxazepam, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV Infections
Interventions: Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more

Conditions: Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
Interventions: Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Fort Lauderdale, Florida

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 1,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 27
States / cities: Los Angeles, California • Torrance, California • Denver, Colorado + 16 more

Conditions: HIV Infections
Interventions: Zidovudine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Nashville, Tennessee

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Birmingham, Alabama • San Diego, California • Worcester, Massachusetts

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV-1
Interventions: Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more

Conditions: HIV Infections
Interventions: Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 5
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Conditions: HIV
Interventions: Truvada, Combivir, Trizivir; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, Zidovudine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 4 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 18
States / cities: Birmingham, Alabama • San Francisco, California • San Jose, California + 11 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 24 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 13 more

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 2 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 12
States / cities: Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
Interventions: Zidovudine, Tocilizumab, Valganciclovir (VGC); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Stavudine, Zidovudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 44
States / cities: Tucson, Arizona • Berkeley, California • Los Angeles, California + 31 more

Conditions: HIV Infections
Interventions: Zidovudine, AS-101; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: Trizivir, atazanavir, Combivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 43
States / cities: Bakersfield, California • Los Angeles, California • Oakland, California + 35 more

Search by objective public record fields.

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy

The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)

A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

Evaluation of Patients Who Have Not Had Success With Zidovudine

Zidovudine and Lamivudine Given Once Versus Twice Daily

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients

A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV